Therapeutic Drug Monitoring · 2009 · 53 citations · 27 references
PharmacyOncologyPharmacokineticsBiosensorsCancer PharmacologyChemotherapyAntibody CharacterizationCancer NanomedicineImmunoassay AnalysisImmunoassay DevelopmentNanomedicinePharmacokinetics Of Monoclonal AntibodiesAssayLiquid Chromatography-mass SpectrometryLiquid Chromatography-mass Spectrometry AnalysisLower Limit Of QuantificationLower Limit Of QuantitationMulticenter TrialsNanoparticle-based ImmunoassaysTandem Mass Spectrometry Analysis
Background: 5-Fluorouracil (5-FU) is the most widely used chemotherapy drug, primarily against gastrointestinal, head and neck, and breast cancers. 5-FU has large pharmacokinetic variability resulting in unexpected toxicity or ineffective treatment. Therapeutic drug management of 5-FU minimizes toxicity and improves outcome. A nanoparticle-based immunoassay was developed to provide oncologists with a rapid, cost-effective tool for determining 5-FU plasma concentrations. Methods: Monoclonal antibodies, bound to nanoparticles, were used to develop an immunoassay for the Olympus AU400. Assay precision, linearity, calibration stability, and limit of detection were run at multiple centers; interference, cross-reactivity, lower limit of quantitation and recovery at 1 center. Clinical samples collected from 4 cancer centers were analyzed for 5-FU concentrations by liquid chromatography-tandem mass spectrometry and compared with the immunoassay results. Results: With calibrators from 0 to 1800 ng/mL 5-FU and autodilution, concentrations up to 9000 ng/mL could be determined. Time to first result was 10 minutes, and 400 samples per hour could be quantitated from a standard curve stored for >30 days. Imprecision across all laboratories was <5%, and the assay was linear upon dilution over the entire range. Cross-reactivities for dihydro-5-FU, uracil, capecitabine, and tegafur were <1%, 9.9%, 0.05%, and 0.23%, respectively. The limit of detection was 52 ng/mL with a lower limit of quantitation of 86 ng/mL. Assay results of clinical samples (93-1774 ng/mL) correlated with liquid chromatography-tandem mass spectrometry results: (R = 0.9860, slope 1.035, intercept 10.87 ng/mL). Conclusions: This novel immunoassay is suitable for quantitating 5-FU plasma concentrations with advantages of speed, small sample size, minimal sample pretreatment, and application on automated instrumentation. These advantages enable efficient therapeutic drug management of 5-FU in clinical practice.
27
Érick Gamelin, R. Delva, J H Jacob et al. · Journal of Clinical Oncology · 2008 · 341 citations
Pharmacy, Oncology, Pharmacokinetics +17
Influence of sex and age on fluorouracil clearance.
G. Milano, M C Etienne, E. Cassuto‐Viguier et al. · Journal of Clinical Oncology · 1992 · 259 citations
Pharmacy, Oncology, Pharmacokinetics +15
Érick Gamelin, M. Boisdron‐Celle, Véronique Guerin‐Meyer et al. · Journal of Clinical Oncology · 1999 · 205 citations